WebJul 1, 2024 · Patients with completely resected pathologic stage II-IIIA (TNM 7th edition) nonsquamous NSCLC were randomly assigned to receive either pemetrexed (500 … WebJul 1, 2024 · Background/aim: Cisplatin combined with pemetrexed disodium heptahydrate (pemetrexed) is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer. However, its growth-inhibitory effects on KRAS-dependent lung cancer as monotherapy and combination therapy are not well understood.
National Center for Biotechnology Information
WebSep 5, 2024 · Pemetrexed with or without maintenance has demonstrated promising outcomes in previous reports for NSCLC patients. As reported by the PARAMOUNT study, [3] selection of a pemetrexed plus cisplatin maintenance treatment is a vital factor for improved effectiveness and reduced side effects for NS-NSCLC patients. WebJul 1, 2024 · Patients with completely resected pathologic stage II-IIIA (TNM 7th edition) nonsquamous NSCLC were randomly assigned to receive either pemetrexed (500 mg/m2, day 1) plus cisplatin (75 mg/m2, day 1) or vinorelbine (25 mg/m2, days 1 and 8) plus cisplatin (80 mg/m2, day 1) with stratification by sex, age, pathologic stage, … how to spend kindle points
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus ... - PubMed
WebJul 13, 2024 · Additional regimens may be added over time, particularly as treatment for non-small cell lung cancer evolves. This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with non-small cell lung cancer. WebDec 21, 2024 · Systemic chemotherapy with pemetrexed and cisplatin has been the cornerstone of treatment for advanced pleural mesothelioma since 2004, when the EMPHACIS trial demonstrated an improvement in response rate, time to progression, and overall survival (OS) for this combination compared with cisplatin alone. 1 Subsequent … WebMar 9, 2024 · Key Points. Question Are frontline therapies recommended for malignant pleural mesothelioma (MPM) associated with patient benefits?. Findings In this comparative effectiveness study of 1501 participants, the statistical robustness of the Mesothelioma Cisplatin Pemetrexed Study (MPS), Mesothelioma Avastin Cisplatin Pemetrexed … how to spend it ft